Encodia, a San Diego firm developing DNA‑tagged peptide protein sequencing (ProteoCode), has ceased operations and moved to liquidate laboratory equipment, according to reports and a former employee post. The company, launched by veterans from next‑generation sequencing and previously backed with a Series C and $75 million in funding, made an assignment for the benefit of creditors in California last November. Encodia’s closure underscores the capital intensity and commercialization challenges in proteomics and single‑molecule protein sequencing, and may leave gaps for customers and partners relying on its platform.